Unexpected Polypeptides Pop Up in Huntington’s Disease
In a process known as repeat-associated non-ATG translation, neurons and glia make alanine, serine, cysteine, and leucine chains from the huntingtin gene.
6397 RESULTS
Sort By:
In a process known as repeat-associated non-ATG translation, neurons and glia make alanine, serine, cysteine, and leucine chains from the huntingtin gene.
Both antibodies might be working, experts say, but the latest data released at the CTAD conference remain tantalizingly unclear. Trialists urgently need progression predictors and better outcome measures.
Gantenerumab, Aducanumab: Bobbing Up and Down While Navigating Currents of Trial Design Outcomes, Outcomes: Cognition is Crux of New Alzheimer’s Trials Truly New to Déjà Vu: Investigational Therapy News at CTAD Truly New to Déjà Vu: For Five Hopefuls, Lig
The CTAD conference featured discussion among many scientists of how to measure a drug’s effect in pre-dementia patients who are so mildly impaired that established tools have trouble picking up improvement. Better cognitive tools are needed.
Several therapeutic approaches in Phase 3 reported updates at the CTAD conference earlier this month in Barcelona. Read about levetiracetam, deep brain stimulation, and scyllo-inositol.
At CTAD, a handful of candidate therapies were reported to have flamed out in Phase 2. They were unable to show efficacy. A new antipsychotic is entering the ring.
At CTAD, investigational Phase 1 drugs include a repackaged and a new anti-amyloid, a tau vaccine, and a repurposed cancer drug.
The leaders of two large European trials report that promoting cardiac health, exercise, and mental activity helped maintained cognition in older adults.
Forget transgenics for a moment. Large collections of inbred and outbred mice could be an untapped treasure trove for Alzheimer’s researchers.
Researchers at this year’s SfN meeting detailed different strategies and outcomes of passive and active vaccines.
Mouse lines made by two different labs replicate the molecular pathology, but not the neurodegeneration, of ALS and FTD based on C9ORF72 expansions.
The BRCA1 protein protects neurons from DNA damage, but levels tumble in Alzheimer’s disease.
NIH announced a five-year study of Alzheimer’s biomarkers in middle-aged people with Down’s syndrome.
Trials of gene therapy for spinomuscular atrophy and stem cell treatments for ALS look promising.
Gene and Stem Cell Therapies Make Strong Showing at ALS/MND Meeting Help for Speech, Swallowing, and Salivation Problems in ALS Does Free Radical Scavenger Edaravone Slow ALS? SOD1, Tau Swept Up in Prion-like Biology at ALS Meeting At the International Sy